Mark Warne was appointed as Chief Executive of the Company on 2 July 2018. Mark, who joined deepmatter® as a Non-Executive Director in September 2015, also served as its Executive Chairman between April 2017 and July 2018. Mark is widely recognised in the UK and international life sciences sector, having spent almost ten years at IP Group plc, a leading intellectual property commercialisation company, where he led the Healthcare team. He managed a portfolio of £330m of net assets in 2016/17 and represented IP Group on the boards of both listed and private companies. In 2018, concurrent with the integration of Touchstone Innovations into IP Group, Mark became a Partner in the Life Sciences division. He joined IP Group from pre-clinical drug discovery CRO Exelgen, where he was Managing Director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry. He serves as a Non-Executive Director on the board of Ixico Plc and as an advisor for Angelini Ventures.
